FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085869089> ?p ?o ?g. }

• W2085869089 endingPage "11" @default.
• W2085869089 startingPage "1" @default.
• W2085869089 abstract "Two hundred ninety patients with acute myocardial infarction were treated according to random assignment with an intravenous infusion of either 80 mg of recombinant tissue plasminogen activator (rt-PA) over 3 h or 1.5 million units of streptokinase over 1 h. Patients received an intravenous bolus of heparin (5,000 U [USP]) before pretreatment coronary angiography and a continuous infusion (1,000 U/h) starting 3 h later. The frequency of major and minor hemorrhagic events (33% rt-PA, 31% streptokinase) and associated transfusions (22% rt-PA, 20% streptokinase) were comparable in both groups. More than 70% of bleeding episodes in each group occurred at catheterization or vascular puncture sites. Precipitable fibrinogen levels, measured in plasma samples collected in the presence of a protease inhibitor (aprotinin), declined in rt-PA and streptokinase groups by averages of 26 and 57% at 3 h and by 33 and 58% at 5 h, respectively (rt-PA versus streptokinase, p less than 0.001). At 5 h the plasma plasminogen declined by 57% (rt-PA) and 82% (streptokinase) (p less than 0.001); plasma fibrin(ogen) degradation products were higher in streptokinase-treated patients (244 +/- 12 micrograms/ml, mean +/- SE) than in rt-PA-treated patients (97 +/- 9 micrograms/ml, p less than 0.001). At 27 h, plasma fibrinogen and plasminogen levels were lower and fibrin(ogen) degradation products higher than pretreatment levels in both groups. The frequency of hemorrhagic events was higher in patients with greater changes in plasma factors at 5 h; within treatment groups the levels of fibrin(ogen) degradation products correlated with bleeding complications (p less than 0.005). Thus, in the doses administered, rt-PA induces systemic fibrinogenolysis that is substantially less intense than that induced by streptokinase. The high frequency of bleeding encountered is related to the protocol used, including vigorous anticoagulation, arterial punctures and thrombolytic therapy. These findings emphasize the need for avoidance of invasive procedures and for meticulous care in the selection and management of patients subjected to thrombolytic therapy." @default.
• W2085869089 created "2016-06-24" @default.
• W2085869089 creator A5020399853 @default.
• W2085869089 creator A5031090287 @default.
• W2085869089 creator A5044699009 @default.
• W2085869089 creator A5051549084 @default.
• W2085869089 creator A5064611672 @default.
• W2085869089 creator A5075187080 @default.
• W2085869089 creator A5076354428 @default.
• W2085869089 creator A5080466261 @default.
• W2085869089 creator A5083179513 @default.
• W2085869089 creator A5086275373 @default.
• W2085869089 date "1988-01-01" @default.
• W2085869089 modified "2023-09-29" @default.
• W2085869089 title "Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase" @default.
• W2085869089 cites W1904357536 @default.
• W2085869089 cites W1983126671 @default.
• W2085869089 cites W2000014961 @default.
• W2085869089 cites W2003924330 @default.
• W2085869089 cites W2004414131 @default.
• W2085869089 cites W2008747427 @default.
• W2085869089 cites W2009005487 @default.
• W2085869089 cites W2018259321 @default.
• W2085869089 cites W2038431234 @default.
• W2085869089 cites W2041135180 @default.
• W2085869089 cites W2042162388 @default.
• W2085869089 cites W2047981092 @default.
• W2085869089 cites W2060132692 @default.
• W2085869089 cites W2078635736 @default.
• W2085869089 cites W2079466233 @default.
• W2085869089 cites W2081336561 @default.
• W2085869089 cites W2092537384 @default.
• W2085869089 cites W2100982071 @default.
• W2085869089 cites W2106487953 @default.
• W2085869089 cites W2137881666 @default.
• W2085869089 cites W2146083057 @default.
• W2085869089 cites W2336267479 @default.
• W2085869089 cites W2336627615 @default.
• W2085869089 cites W2402623730 @default.
• W2085869089 cites W2411570109 @default.
• W2085869089 cites W4235858444 @default.
• W2085869089 cites W4250308127 @default.
• W2085869089 doi "https://doi.org/10.1016/0735-1097(88)90158-1" @default.
• W2085869089 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3121710" @default.
• W2085869089 hasPublicationYear "1988" @default.
• W2085869089 type Work @default.
• W2085869089 sameAs 2085869089 @default.
• W2085869089 citedByCount "931" @default.
• W2085869089 countsByYear W20858690892012 @default.
• W2085869089 countsByYear W20858690892013 @default.
• W2085869089 countsByYear W20858690892014 @default.
• W2085869089 countsByYear W20858690892015 @default.
• W2085869089 countsByYear W20858690892016 @default.
• W2085869089 countsByYear W20858690892017 @default.
• W2085869089 countsByYear W20858690892018 @default.
• W2085869089 countsByYear W20858690892019 @default.
• W2085869089 countsByYear W20858690892020 @default.
• W2085869089 countsByYear W20858690892021 @default.
• W2085869089 countsByYear W20858690892022 @default.
• W2085869089 countsByYear W20858690892023 @default.
• W2085869089 crossrefType "journal-article" @default.
• W2085869089 hasAuthorship W2085869089A5020399853 @default.
• W2085869089 hasAuthorship W2085869089A5031090287 @default.
• W2085869089 hasAuthorship W2085869089A5044699009 @default.
• W2085869089 hasAuthorship W2085869089A5051549084 @default.
• W2085869089 hasAuthorship W2085869089A5064611672 @default.
• W2085869089 hasAuthorship W2085869089A5075187080 @default.
• W2085869089 hasAuthorship W2085869089A5076354428 @default.
• W2085869089 hasAuthorship W2085869089A5080466261 @default.
• W2085869089 hasAuthorship W2085869089A5083179513 @default.
• W2085869089 hasAuthorship W2085869089A5086275373 @default.
• W2085869089 hasBestOaLocation W20858690891 @default.
• W2085869089 hasConcept C126322002 @default.
• W2085869089 hasConcept C164705383 @default.
• W2085869089 hasConcept C181199279 @default.
• W2085869089 hasConcept C185592680 @default.
• W2085869089 hasConcept C203014093 @default.
• W2085869089 hasConcept C2776336681 @default.
• W2085869089 hasConcept C2776572282 @default.
• W2085869089 hasConcept C2776641609 @default.
• W2085869089 hasConcept C2777995511 @default.
• W2085869089 hasConcept C2779036427 @default.
• W2085869089 hasConcept C2779581417 @default.
• W2085869089 hasConcept C2779679481 @default.
• W2085869089 hasConcept C2780799893 @default.
• W2085869089 hasConcept C2781071845 @default.
• W2085869089 hasConcept C2909373784 @default.
• W2085869089 hasConcept C42219234 @default.
• W2085869089 hasConcept C500558357 @default.
• W2085869089 hasConcept C54173615 @default.
• W2085869089 hasConcept C55493867 @default.
• W2085869089 hasConcept C71924100 @default.
• W2085869089 hasConceptScore W2085869089C126322002 @default.
• W2085869089 hasConceptScore W2085869089C164705383 @default.
• W2085869089 hasConceptScore W2085869089C181199279 @default.
• W2085869089 hasConceptScore W2085869089C185592680 @default.
• W2085869089 hasConceptScore W2085869089C203014093 @default.
• W2085869089 hasConceptScore W2085869089C2776336681 @default.

• next